Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

EULAR 2015: RA Research Shows Imperfect Guidelines, Suggests Strategies with Biologics

Thomas R. Collins  |  Issue: August 2015  |  August 17, 2015

Studies suggest that methotrexate use boosts the effectiveness of biologics.

Studies suggest that methotrexate use boosts the effectiveness of biologics.
Image Credit: Syda Productions/shutterstock.com

ROME, Italy—Even with classification criteria that have been updated and refined over time, rheumatoid arthritis is still a diagnosis that ultimately has to be made with clinical judgment, said Ronald van Vollenhoven, MD, PhD, professor of medicine and chief of clinical therapy research in inflammatory diseases at the Karolinska University in Sweden. His remarks came during a review of new literature at EULAR 2015, the annual congress of the European League Against Rheumatism (EULAR).

Sensitivity Challenges

Studies on the 2010 ACR/EULAR classification criteria for rheumatoid arthritis (RA) seem to show that they are not as sensitive as the 1987 criteria, even though one of the intentions of the newer criteria was that they were going to be more sensitive, Dr. van Vollenhoven said. Studies have also found that agreement is “not great” between the older criteria, the newer criteria and expert opinion.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Also, patients identified with the newer criteria seem to have lower progression rates than those identified using the older ones, he said.

“The patients who fulfilled the newer criteria do not necessarily have as bad a prognosis as those who fulfilled the previous criteria,” he said. “The 2010 criteria might be identifying slightly milder (diseased) patient populations.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

A systematic literature review late last year, in which RA cases identified using the 2010 criteria were then subjected to expert opinion, found that the sensitivity rate of the criteria was 80% and the specificity rate was just 60%. So a declaration that someone has RA, based on the criteria, would be wrong 1 in 5 times. And a declaration that someone does not have RA would be wrong 2 in 5 times, he said.2

“I do not think that you have to completely base your decision on those criteria,” Dr. van Vollenhoven said. “You should use clinical judgment.”

Importance of Imaging

A study last year found that using MRI along with the 2010 criteria improves the diagnostic probability of early RA, he noted.

“I think imaging is going to become more and more important as an ancillary diagnostic tool,” he said.

Imaging is going to become more & more important as an ancillary diagnostic tool.

Studies out of his center have found that musculoskeletal ultrasound can improve diagnostic certainty and found that a 12-biomarker panel, known as the MBDA, can help predict which patients will respond better to biologic therapy and which will respond better to non-biologic DMARD therapy.3-5

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsEULAR/OtherMeeting ReportsResearch RheumRheumatoid Arthritis Tagged with:ClinicalDiagnosisEULARpatient carePractice ManagementResearchRheumatoid arthritis

Related Articles

    Is Predisone 3 mg/day an Appropriate Dose for Patients with Rheumatoid Arthritis?

    April 1, 2013

     Long-term, low-dose prednisone at less than 5 mg/day appears tolerable and effective for many patients with rheumatoid arthritis (RA)

    Chronotherapy with Glucorticoids in Rheumatoid Arthritis

    January 17, 2011

    Time is of the essence in balancing risks and benefits

    The Key to Early Rheumatoid Arthritis

    September 1, 2010

    The conundrum of classification versus diagnosis

    Revising Fibromyalgia: One Year Later

    July 12, 2011

    The 2010 ACR fibromyalgia criteria capture the broader clinical picture and help ensure more appropriate diagnosis and management by primary care

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences